TO STUDY THE ROLE OF ZOLEDRONIC ACID IN OSTEOPROTIC PATIENTS

s n medical college0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Adults aged between 50 to 89 years.
•2.A bone mineral density T score of â??2.5 or less at the femoral neck, with or without evidence of existing vertebral fracture, or a T score of â??1.5 or less, with radiologic evidence of at least two mild vertebral fractures or one moderate vertebral fracture (Previous use of oral bisphosphonates was allowed, with the duration of the washout period dependent on previous use (e.g., previous use of >=48 weeks required 2 years of washout).

•1.Previous use of parathyroid hormone or sodium fluoride,
•2.Use of anabolic steroids or growth hormone within 6 months before trial entry or oral or intravenous systemic corticosteroids within 12 months, and any previous use of strontium.
•3.Patients with a serum calcium level of more than 2.75 mmol per liter or less than 2.00 mmol per liter were ineligible, as were patients with a calculated creatinine clearance of less than 30.0 ml per minute at either of two baseline visits or urine dipstick results of more than 2+ for protein, without evidence of contamination or bacteriuria.

发起方

s n medical college